- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Renal cell carcinoma (RCC)
- Meeting Date: March 2021
- Public Summary Document (PSD) March 2021 PBAC Meeting - (PDF 1727KB)
- Public Summary Document (PSD) March 2021 PBAC Meeting - (Word 714KB)
Avelumab – March 2021
Avelumab (renal cell carcinoma): Solution concentrate for I.V. infusion 200 mg in 10 mL; Bavencio®
Last updated
2 July 2021